Working… Menu

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02330796
Recruitment Status : Completed
First Posted : January 5, 2015
Last Update Posted : October 5, 2016
Information provided by (Responsible Party):
Revive Therapeutics, Ltd.

Brief Summary:
A Phase IIA, open-label, multicenter, active-controlled, parallel-group clinical trial designed to evaluate the safety and efficacy of two doses of Bucillamine compared with low-dose Colchicine in the treatment of patients with acute gout flare.

Condition or disease Intervention/treatment Phase
Gout Drug: Bucillamine Drug: Colchicine Phase 2

Detailed Description:
To evaluate the safety and tolerability of two regimens of Bucillamine 100 mg (900 mg and 1,800 mg) over seven days of treatment compared with Colchicine 0.6 mg (1.8 mg) in the treatment of patients with acute gout flare

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : April 2015
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Gout
MedlinePlus related topics: Gout
Drug Information available for: Colchicine

Arm Intervention/treatment
Experimental: Arm A
Bucillamine (900 mg total dose over 7 days)
Drug: Bucillamine
Bucillamine Tablets

Experimental: Arm B
Bucillamine (1,800 mg total dose over 7 days)
Drug: Bucillamine
Bucillamine Tablets

Active Comparator: Arm C
Colchicine (1.8 mg total dose in 2 doses taken 1 hour apart)
Drug: Colchicine

Primary Outcome Measures :
  1. Composite measure of adverse events (AEs), physical examinations, electrocardiograms (ECGs), vital signs, clinical laboratory evaluations, medical history, and prior/concomitant medications [ Time Frame: 7 days ]
  2. At least a 50% reduction in target joint pain PI-NRS score from baseline without using rescue drug [ Time Frame: 72 hours ]

Secondary Outcome Measures :
  1. A greater than or equal to 50% reduction in target joint pain PI-NRS score from baseline at 24 hours and 48 hours post-dose without using rescue drug [ Time Frame: 24 hrs and 48 hrs ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must present with confirmed diagnosis of gout, meeting the American College of Rheumatology (ACR) 1977 preliminary criteria for the classification of acute arthritis of primary gout
  • Subjects must have experienced at least one (1) acute gouty arthritic attack in the 12 months prior to randomization
  • Presence of acute gout flare for no longer than 3 days at Visit 2
  • Pain intensity at inclusion (Visit 2) of 7-10 on 11-point PI-NRS (defined as severe gout flare for this study)
  • All patients should not have contraindications for Colchicine use
  • Subjects with a history of intolerance to NSAIDs (Checklists Checklist 1)
  • Subjects with significant medical contraindication to NSAIDs (Checklist 2)
  • Subjects with past failure of NSAIDs to control acute gouty arthritis attacks in the previous 12 months (Checklist 3)
  • Regarding significant medical contraindication to NSAIDs or past failure of NSAIDs to control acute gouty arthritis attacks in the previous 12 months (i.e. refractoriness to NSAIDs) the patient must meet one of below criteria:

    1. At least one historical episode within the previous 12 months of being refractory or intolerant to NSAIDs that makes the physician concerned to use NSAIDs for a subsequent acute gout attack
    2. The current (referring) physician judgment is that NSAIDs are not appropriate for treating the patient's gouty arthritis flare which may be due to changes in patient status such as worsening co-morbid conditions or co-medications (e.g., GI tract disease, renal insufficiency, hypertension, fluid retention, concurrent use of diuretics and/or an angiotensin converting enzyme inhibitor or angiotensin receptor blocker, especially in CKD)
  • Subjects must be willing and able to give written informed consent. A HIPAA and/or state privacy consent must also be signed
  • Subjects must be able to swallow tablets
  • Use of permitted concomitant medications must be unchanged in dose and or frequency, 30 days prior to screening
  • Adequate organ function, evidenced by the following laboratory results within 90 days prior to randomization (historical lab results are acceptable).
  • Creatine clearance > 45 mL/min based on Cockroft-Gault glomerular filtration rate (GFR) estimation
  • For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of conception.

Exclusion Criteria:

  • Subjects with rheumatoid arthritis, psoriatic arthritis, evidence/suspicion of infectious/septic arthritis, acute polyarticular gout (4 or more joints), with arthritis due to any cause other than gout that may confound any study assessments per Investigator discretion
  • Subjects who have experienced >2 acute gouty arthritic attacks per month, or >12 attacks overall, in the 6 months prior to randomization
  • Subjects with a history of myocardial infarction, unstable angina, cerebrovascular events, or coronary artery bypass grafting within the previous 6 months prior to screening
  • Subjects with a Body Mass Index >45 kg/m2; calculated as body weight (kg)/height (m)2 at Screening Visit
  • Subjects with acute or chronic infections including known HIV and/or Hepatitis B or C
  • Uncontrolled hypertension (>160/90 mmHg seated) (if the first set of BP assessment meets the definition of uncontrolled hypertension, a second set of BP assessments may be performed after the patient has rested for at least 30 min. If the second set of BP assessments does not meet the definition of uncontrolled hypertension the patient will be eligible for participation)
  • Subjects with proteinuria ≥1+ or ≥30 mg on dipstick urinalysis that is confirmed on repeat assessment within 24 hours
  • Subjects with significant heart failure and activity impairment (Class III-IV of the New York Heart Association (NYHA)
  • Subjects with any history of malignancy, 5 years prior to randomization
  • Subjects with CKD NKF stages 3B -5 chronic renal dysfunction (eGFR <45 mL/min/1.73m2 acc. to Cockcroft Gault formula)
  • Subjects with serious hepatic disorder (Child-Pugh scores B or C)
  • Subjects who have not washed out of dopamine antagonists or depleting drugs excluding anticholinergics and/or antihistamines with anticholinergic effects at least 14 days prior to Day 1 (Visit 2)
  • Subjects with a documented history of alcohol or substance abuse within the 12 months prior to randomization(consumption of >21 units of alcohol per week is considered alcohol abuse)
  • Subjects with significant CNS effects including vertigo and dizziness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02330796

Layout table for location information
United States, California
West Coast Research
San Roman, California, United States, 94582
United States, Texas
Texas Physicians Research Medical Group
Arlington, Texas, United States, 76015
Sun Research Institute
San Antonio, Texas, United States, 78215
Sponsors and Collaborators
Revive Therapeutics, Ltd.

Layout table for additonal information
Responsible Party: Revive Therapeutics, Ltd. Identifier: NCT02330796     History of Changes
Other Study ID Numbers: REV-201
First Posted: January 5, 2015    Key Record Dates
Last Update Posted: October 5, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Gout Suppressants
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Protective Agents